@article{2a2dbbf1bd854f12994e79f2021ada56,
title = "Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis",
abstract = "Background: Although American Society of Clinical Oncology and European Society for Medical Oncology guidelines have identified the negative prognostic factors that clinicians have to consider when treating their patients with stage II colon cancer (CC), the role of histological subtype is controversial. Subjects, Materials, and Methods: The randomized, multicenter, phase III TOSCA trial compared 3 versus 6 months of fluoropyrimidine-oxaliplatin adjuvant chemotherapy in 3,759 patients with high-risk stage II or stage III CC. The objective of this substudy was to evaluate the influence of histological subtypes on the impact of the treatment duration of adjuvant chemotherapy in terms of relapse-free survival (RFS) and overall survival (OS) in 85 mucinous adenocarcinoma (MUC) and 389 nonmucinous adenocarcinoma (NMUC) patients with high-risk stage II, grade 3 CC. Results: A significant interaction between treatment duration and histology was observed in both RFS (p =.027) and OS (p =.017). In the subgroup of patients with MUC, worse RFS (adjusted hazard ratio [HR], 3.95; 95% confidence interval [CI], 1.03–15.17; p =.045) and OS (HR, 9.56; 95% CI, 1.14–79.98; p =.037) were detected for patients treated in the 3-month arm. No statistically significant differences were found in the subgroup of patients with NMUC. Conclusion: Patients with MUC, grade 3, stage II CC require special attention and may need 6 months of oxaliplatin-based chemotherapy. Larger studies are required to assess the combined use of histology and other prognostic/predictive factors to define the administration of chemotherapy in patients with stage II CC and to improve their prognosis. Implications for Practice: Although ASCO and ESMO guidelines define the prognostic factors for patients with stage II colon cancer to establish the use of adjuvant chemotherapy, the influence of histological subtypes is controversial in this population. This study underscores that patients with grade 3 mucinous adenocarcinomas may need adjuvant chemotherapy with oxaliplatin and fluoropyrimidines for a duration of 6 months rather than 3 months. {\textcopyright} AlphaMed Press 2020",
keywords = "Colorectal cancer, Histological type, Mucinous adenocarcinoma, Oxaliplatin-based adjuvant chemotherapy, Poorly differentiated adenocarcinoma, capecitabine plus oxaliplatin, fluoropyrimidine, fluorouracil, folinic acid, oxaliplatin, adult, Article, cancer adjuvant therapy, cancer prognosis, cancer staging, clinical outcome, colloid carcinoma, colon cancer, comparative study, controlled study, female, histology, human, human tissue, major clinical study, male, middle aged, mucinous cystic neoplasm, multicenter study, multiple cycle treatment, outcome assessment, overall survival, patient compliance, phase 3 clinical trial, priority journal, randomized controlled trial, recurrence free survival, treatment duration, treatment refusal",
author = "G. Rosati and F. Galli and M. Cantore and F. Bergamo and M. Banzi and M.G. Zampino and R. Mattioli and G.G. Cardellino and M. Ronzoni and {Di Bartolomeo}, M. and S. Tamberi and P. Marchetti and L. Rimassa and D. Corsi and A.M. Bochicchio and F. Artioli and R. Labianca and E. Rulli and D. Bilancia and G. Bregni",
note = "Cited By :3 Export Date: 4 February 2021 CODEN: OCOLF Correspondence Address: Rosati, G.; U.O. Oncologia MedicaItaly; email: oncogerry@yahoo.it Chemicals/CAS: fluoropyrimidine, 675-21-8; fluorouracil, 51-21-8; folinic acid, 58-05-9; oxaliplatin, 61825-94-3 Funding details: Agenzia Italiana del Farmaco, Ministero della Salute, AIFA Funding text 1: This work was supported by Grant FARM5RWTWZ from the AIFA (Agenzia Italiana del Farmaco). References: Sargent, D., Sobrero, A., Grothey, A., Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials (2009) J Clin Oncol, 27, pp. 872-877; Gray, R., Barnwell, J., Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study (2007) Lancet, 370, pp. 2020-2029; Figueredo, A., Charette, M.L., Maroun, J., Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group (2004) J Clin Oncol, 22, pp. 3395-3407; Andr{\'e}, T., Boni, C., Mounedji-Boudiaf, L., Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (2004) N Engl J Med, 350, pp. 2343-2351; Buyse, M., Piedbois, P., Should Dukes{\textquoteright} B patients receive adjuvant therapy? A statistical perspective (2001) Semin Oncol, 28, pp. 20-24; Kannarkatt, J., Joseph, J., Kuriali, P.C., Adjuvant chemotherapy for stage II colon cancer: A clinical dilemma (2017) J Oncol Pract, 13, pp. 233-241; Bagante, F., Spolverato, G., Beal, E., Impact of histological subtype on the prognosis of patients undergoing surgery for colon cancer (2018) J Surg Oncol, 117, pp. 1355-1363; Kanda, M., Oba, K., Aoyama, T., Clinical signatures of mucinous and poorly differentiated subtypes of colorectal adenocarcinomas by a propensity score analysis of an independent patient database from three phase III trials (2018) Dis Colon Rectum, 61, pp. 461-471; Sobrero, A., Lonardi, S., Rosati, G., FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the Italian three or six colon adjuvant trial (2018) J Clin Oncol, 36, pp. 1478-1485; Bosman, F.T., Carneiro, F., Hruban, R.H., (2010) WHO Classification of Tumours of the Digestive System, , 4th ed., Geneva, World Health Organization Classification of Tumours; Luo, C., Cen, S., Ding, G., Mucinous colorectal adenocarcinoma: Clinical pathology and treatment options (2019) Cancer Commun, 39; Ribic, C.M., Sargent, D.J., Moore, M.J., Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer (2003) N Engl J Med, 349, pp. 247-257; Hutchins, G., Southward, K., Handley, K., Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer (2011) J Clin Oncol, 29, pp. 1261-1270; Negri, F.V., Wotherspoon, A., Cunningham, D., Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer (2005) Ann Oncol, 16, pp. 1305-1310; Mekenkamp, L.J., Heesterbeek, K.J., Koopman, M., Mucinous adenocarcinomas: Poor prognosis in metastatic colorectal cancer (2012) Eur J Cancer, 48, pp. 501-509; Catalano, V., Loupakis, F., Graziano, F., Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy (2009) Br J Cancer, 100, pp. 881-887; Maisano, R., Azzarello, D., Maisano, M., Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer (2012) J Chemother, 24, pp. 212-216; Hugen, N., Verhoeven, R.H., Radema, S.A., Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma (2013) Ann Oncol, 24, pp. 2819-2824; Catalano, V., Loupakis, F., Graziano, F., Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer (2012) Ann Oncol, 23, pp. 135-141; Kim, S.H., Shin, S.J., Lee, K.Y., Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: A retrospective cohort study (2013) Ann Surg Oncol, 20, pp. 3407-3413; Sakamoto, J., Ohashi, Y., Hamada, C., Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials (2004) J Clin Oncol, 22, pp. 484-492; Park, J.S., Huh, J.W., Park, Y.A., Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer (2015) Medicine (Baltimore), 94; Yoshioka, Y., Togashi, Y., Chikugo, T., Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas (2015) Cancer, 121, pp. 4359-4368; Foda, A.A., El-Hawary, A.K., Hamed, H., Aberrant expression of calretinin, D2-40 and mesothelin in mucinous and non-mucinous colorectal carcinomas and relation to clinicopathological features and prognosis (2016) Pathol Oncol Res, 22, pp. 725-732; Matsuda, C., Ishiguro, M., Teramukai, S., A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial (2018) Eur J Cancer, 96, pp. 54-63; Liu, Q., Luo, D., An, H., Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer (2019) J Cancer, 10, pp. 1209-1215; Langner, C., Harbaum, L., Pollheimer, M.J., Mucinous differentiation in colorectal cancer–Indicator of poor prognosis? (2012) Histopathology, 60, pp. 1060-1072; Yamaguchi, T., Taniguchi, H., Fujita, S., Clinicopathological characteristics and prognostic factors of advanced colorectal mucinous adenocarcinoma (2012) Histopathology, 61, pp. 162-169; Kakar, S., Aksoy, S., Burgart, L.J., Mucinous carcinoma of the colon: Correlation of loss of mismatch repair enzymes with clinicopathologic features and survival (2004) Mod Pathol, 17, pp. 696-700; Barresi, V., Reggiani Bonetti, L., Ieni, A., Prognostic significance of grading based on the counting of poorly differentiated clusters in colorectal mucinous adenocarcinoma (2015) Hum Pathol, 46, pp. 1722-1729",
year = "2020",
doi = "10.1634/theoncologist.2019-0736",
language = "English",
volume = "25",
pages = "e928--e935",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley-Blackwell",
number = "6",
}